IBRX vs. VCYT
IBRX (ImmunityBio, Inc.) and VCYT (Veracyte, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, IBRX returned 1.23%/yr vs 26.09%/yr for VCYT. At a 0.36 correlation, their price movements are largely independent.
Performance
IBRX vs. VCYT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IBRX achieves a 271.72% return, which is significantly higher than VCYT's 27.39% return. Over the past 10 years, IBRX has underperformed VCYT with an annualized return of 1.23%, while VCYT has yielded a comparatively higher 26.09% annualized return.
IBRX
- 1D
- 5.29%
- 1M
- -8.57%
- YTD
- 271.72%
- 6M
- 253.85%
- 1Y
- 159.15%
- 3Y*
- 39.01%
- 5Y*
- -11.31%
- 10Y*
- 1.23%
VCYT
- 1D
- 4.56%
- 1M
- 18.68%
- YTD
- 27.39%
- 6M
- 24.95%
- 1Y
- 99.96%
- 3Y*
- 27.15%
- 5Y*
- 7.43%
- 10Y*
- 26.09%
IBRX vs. VCYT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
IBRX ImmunityBio, Inc. | 271.72% | -22.66% | -49.00% | -0.99% | -16.61% | -54.39% | 251.72% | 226.72% | -74.16% | -21.50% |
VCYT Veracyte, Inc. | 27.39% | 6.31% | 43.95% | 15.93% | -42.40% | -15.82% | 75.29% | 121.94% | 92.65% | -15.63% |
Correlation
The correlation between IBRX and VCYT is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.44 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Jul 28, 2015 | 0.36 |
The correlation between IBRX and VCYT shifts across timeframes, from 0.22 (1 year) to 0.44 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
IBRX:
$7.56B
VCYT:
$4.36B
IBRX:
-$0.89
VCYT:
$1.09
IBRX:
50.27
VCYT:
7.98
IBRX:
$140.98M
VCYT:
$541.74M
IBRX:
$132.23M
VCYT:
$386.89M
IBRX:
-$196.14M
VCYT:
$99.47M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IBRX vs. VCYT — Risk / Return Rank
IBRX
VCYT
IBRX vs. VCYT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ImmunityBio, Inc. (IBRX) and Veracyte, Inc. (VCYT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IBRX | VCYT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.13 | ||
| Sortino ratioReturn per unit of downside risk | -0.24 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.33 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 3.78 | 2.56 | +1.22 |
| Martin ratioReturn relative to average drawdown | 6.49 | 5.59 | +0.90 |
Loading charts...
Drawdowns
IBRX vs. VCYT - Drawdown Comparison
The maximum IBRX drawdown since its inception was -97.30%, which is greater than VCYT's maximum drawdown of -81.19%. Use the drawdown chart below to compare losses from any high point for IBRX and VCYT.
Loading charts...
Drawdown Indicators
| IBRX | VCYT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.30% | -81.19% | -16.11% |
Max Drawdown (1Y)Largest decline over 1 year | -42.34% | -39.23% | -3.11% |
Max Drawdown (3Y)Largest decline over 3 years | -79.34% | -50.09% | -29.25% |
Max Drawdown (5Y)Largest decline over 5 years | -91.75% | -71.54% | -20.21% |
Max Drawdown (10Y)Largest decline over 10 years | -97.03% | -81.19% | -15.84% |
Current DrawdownCurrent decline from peak | -82.58% | -34.10% | -48.48% |
Average DrawdownAverage peak-to-trough decline | -84.38% | -48.31% | -36.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.64% | 17.95% | +6.69% |
Volatility
IBRX vs. VCYT - Volatility Comparison
ImmunityBio, Inc. (IBRX) has a higher volatility of 18.75% compared to Veracyte, Inc. (VCYT) at 15.21%. This indicates that IBRX's price experiences larger fluctuations and is considered to be riskier than VCYT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IBRX | VCYT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.75% | 15.21% | +3.54% |
Volatility (6M)Calculated over the trailing 6-month period | 88.55% | 39.59% | +48.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 104.25% | 60.33% | +43.92% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 113.40% | 64.40% | +49.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.39% | 62.00% | +49.39% |
Dividends
IBRX vs. VCYT - Dividend Comparison
Neither IBRX nor VCYT has paid dividends to shareholders.
Financials
IBRX vs. VCYT - Financials Comparison
This section allows you to compare key financial metrics between ImmunityBio, Inc. and Veracyte, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
IBRX and VCYT have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IBRX has higher volatility (18.75%) compared to VCYT (15.21%). In terms of maximum drawdown, IBRX dropped -97.30% vs VCYT's -81.19%.
VCYT currently has the higher Sharpe Ratio (1.67 vs 1.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IBRX and VCYT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer